FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Launching a series of chronic-disease combination drugs while preparing the first trial of a once-monthly obesity candidate. Also seen: Commercial · sales

  • Presented results for a once-monthly obesity candidate at the American Diabetes Association meeting. Source

Roles often seen at this stageResearch & development · Clinical & PV · Sales & marketing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Kyung Dong Pharm

A maker of chronic-disease medicines such as combination drugs for hypertension, dyslipidaemia and diabetes, plus over-the-counter products, co-developing a once-monthly obesity candidate.

Fenorovan

Marketed

Combination dyslipidaemia drug launched in April 2026.

AUL009

Stage unconfirmed

Once-monthly semaglutide obesity candidate for which a Phase 1 trial plan has been filed.

Completion reported

Presented results for its once-monthly obesity candidate at the American Diabetes Association meeting.

Official role guide

Kyung Dong Pharm careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 경동제약 ↗경동제약 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable
  2. 경동제약, 월 1회 투여 비만치료제 임상 결과 ADA 2026서 발표 ↗한국경제 · Published 2026-06-11 · Sources checked 2026-11-15 · Original unavailable